Activation of CXCR2 by extracellular matrix degradation product acetylated pro-gly-pro has therapeutic effects against sepsis

American Journal of Respiratory and Critical Care Medicine

Volumn 184, Issue 2, 2011, Pages 243-251

  Kim, Sang Doo ^a,b   Lee, Ha Young ^a,f   Shim, Jae Woong ^b   Kim, Hak Jung ^a,b   Yoo, Young Hyun ^b   Park, Joon Seong ^c   Baek, Suk Hwan ^d   Zabel, Brian A ^e   Bae, Yoe Sik ^a,b  

^a Sungkyunkwan University   (South Korea)

^b Dong A University   (South Korea)

^c Ajou University School of Medicine   (South Korea)

^d Yeungnam University College of Medicine   (South Korea)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f Seoul National University   (South Korea)

Author keywords

Acetylated Pro Gly Pro; CXCR2; Sepsis

Indexed keywords

ACETYLATED PROLYLGLYCYLPROLINE; CHEMOKINE RECEPTOR CXCR2; COLLAGEN; FLUORESCEIN ISOTHIOCYANATE; GAMMA INTERFERON; HYDROGEN PEROXIDE; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; INTERFERON PRODUCTION; LEUKOCYTE; MALE; MOUSE; NONHUMAN; ORGAN INJURY; PNEUMONIA; PRIORITY JOURNAL; SEPSIS; SPLEEN CELL;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MALE; MICE; MICE, INBRED C57BL; OLIGOPEPTIDES; PROLINE; RECEPTORS, INTERLEUKIN-8B; SEPSIS;

EID: 80051564350     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201101-0004OC     Document Type: Article

References (37)

1. Cohen J. The immunopathogenesis of sepsis. Nature 2002;420:885-891. (Pubitemid 36019643)
2. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-1310. (Pubitemid 32641789)
3. Aneja R, Fink MP. Promising therapeutic agents for sepsis. Trends Microbiol 2007;15:31-37. (Pubitemid 46038730)
4. Döcke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, Volk HD, Kox W. Monocyte deactivation in septic patients: restoration by IFN-γ treatment. Nat Med 1997;3:678-681. (Pubitemid 27264980)
5. Czermak BJ, Sarma V, Pierson CL, Warner RL, Huber-Lang M, Bless NM, Schmal H, Friedl HP, Ward PA. Protective effects of C5a blockade in sepsis. Nat Med 1999;5:788-792. (Pubitemid 29318613)
6. Calandra T, Echtenacher B, Roy DL, Pugin J, Metz CN, Hültner L, Heumann D, Männel D, Bucala R, Glauser MP. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 2000;6:164-170. (Pubitemid 30082360)
7. Hotchkiss RS, Tinsley KW, Swanson PE, Schmieg RE Jr, Hui JJ, Chang KC, Osborne DF, Freeman BD, Cobb JP, Buchman TG, et al. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol 2001;166:6952-6963. (Pubitemid 32467243)
8. Wang SD, Huang KJ, Lin YS, Lei HY. Sepsis-induced apoptosis of the thymocytes in mice. J Immunol 1994;152:5014-5021.
9. Gogos CA, Drosou E, Bassaris HP, Skoutelis A. Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis 2000;181:176-180. (Pubitemid 30049046)
10. Remick DG, Newcomb DE, Bolgos GL, Call DR. Comparison of the mortality and inflammatory response of two models of sepsis: lipopolysaccharide vs. cecal ligation and puncture. Shock 2000;13:110-116.
11. Ulloa L, Tracey KJ. The "cytokine profile": a code for sepsis. Trends Mol Med 2005;11:56-63.
12. Chapman RW, Phillips JE, Hipkin RW, Curran AK, Lundell D, Fine JS. CXCR2 antagonists for the treatment of pulmonary disease. Pharmacol Ther 2009;121:55-68.
13. Wu L, Ruffing N, Shi X, Newman W, Soler D, Mackay CR, Qin S. Discrete steps in binding and signaling of interleukin-8 with its receptor. J Biol Chem 1996;271:31202-31209. (Pubitemid 26408564)
14. Boisvert WA, Curtiss LK, Terkeltaub RA. Interleukin-8 and its receptor CXCR2 in atherosclerosis. Immunol Res 2000;21:129-137.
15. Baggiolini M, Walz A, Kunkel SL. Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J Clin Invest 1989;84:1045-1049. (Pubitemid 19247571)
16. Mehrad B, Strieter RM, Moore TA, Tsai WC, Lira SA, Standiford TJ. CXC chemokine receptor-2 ligands are necessary components of neutrophil-mediated host defense in invasive pulmonary aspergillosis. J Immunol 1999;163:6086-6094.
17. Cummings CJ, Martin TR, Frevert CW, Quan JM, Wong VA, Mongovin SM, Hagen TR, Steinberg KP, Goodman RB. Expression and function of the chemokine receptors CXCR1 and CXCR2 in sepsis. J Immunol 1999;162:2341-2346. (Pubitemid 29288860)
18. Adams JM, Hauser CJ, Livingston DH, Lavery RF, Fekete Z, Deitch EA. Early trauma polymorphonuclear neutrophil responses to chemokines are associated with development of sepsis, pneumonia, and organ failure. J Trauma 2001;51:452-456.
19. Ness TL, Hogaboam CM, Strieter RM, Kunkel SL. Immunomodulatory role of CXCR2 during experimental septic peritonitis. J Immunol 2003;171:3775-3784. (Pubitemid 37254583)
20. Gando S, Kameue T, Matsuda N, Hayakawa M, Ishitani T, Morimoto Y, Kemmotsu O. Combined activation of coagulation and inflammation has an important role in multiple organ dysfunction and poor outcome after severe trauma. Thromb Haemost 2002;88:943-949. (Pubitemid 36018780)
21. Kaneider NC, Agarwal A, Leger AJ, Kuliopulos A. Reversing systemic inflammatory response syndrome with chemokine receptor pepducins. Nat Med 2005;11:661-665. (Pubitemid 40868307)
22. Pfister RR, Haddox JL, Sommers CI, Lam KW. Identification and synthesis of chemotactic tripeptides from alkali-degraded whole cornea: a study of N-acetyl-proline-glycine-proline and N-methyl-proline-glycine-proline. Invest Ophthalmol Vis Sci 1995;36:1306-1316.
23. Gaggar A, Jackson PL, Noerager BD, O'Reilly PJ, McQuaid DB, Rowe SM, Clancy JP, Blalock JE. A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation. J Immunol 2008;180:5662-5669.
24. Weathington NM, van Houwelingen AH, Noerager BD, Jackson PL, Kraneveld AD, Galin FS, Folkerts G, Nijkamp FP, Blalock JE. A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation. Nat Med 2006;12:317-323. (Pubitemid 43355080)
25. Bae YS, Lee HY, Jo EJ, Kim JI, Kang HK, Ye RD, Kwak JY, Ryu SH. Identification of peptides that antagonize formyl peptide receptor-like 1-mediated signaling. J Immunol 2004;173:607-614. (Pubitemid 38797390)
26. Yan JJ, Jung JS, Lee JE, Lee J, Huh SO, Kim HS, Jung KC, Cho JY, Nam JS, Suh HW, et al. Therapeutic effects of lysophosphatidylcholine in experimental sepsis. Nat Med 2004;10:161-167. (Pubitemid 38524886)
27. Liu D, Zeng BX, Zhang SH, Yao SL. Rosiglitazone, an agonist of peroxisome proliferator-activated receptor γ, reduces pulmonary inflammatory response in a rat model of endotoxemia. Inflamm Res 2005;54:464-470. (Pubitemid 41690375)
28. Wang J, Silva JP, Gustafsson CM, Rustin P, Larsson NG. Increased in vivo apoptosis in cells lacking mitochondrial DNA gene expression. Proc Natl Acad Sci USA 2001;98:4038-4043. (Pubitemid 32249894)
29. Bae YS, Bae H, Kim Y, Lee TG, Suh PG, Ryu SH. Identification of novel chemoattractant peptides for human leukocytes. Blood 2001;97:2854-2862.
30. White JR, Lee JM, Young PR, Hertzberg RP, Jurewicz AJ, Chaikin MA, Widdowson K, Foley JJ, Martin LD, Griswold DE, et al. Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J Biol Chem 1998;273:10095-10098. (Pubitemid 28227606)
31. Riedemann NC, Guo RF, Ward PA. Novel strategies for the treatment of sepsis. Nat Med 2003;9:517-524. (Pubitemid 36597096)
32. Roos D, van Bruggen R, Meischl C. Oxidative killing of microbes by neutrophils. Microbes Infect 2003;5:1307-1315. (Pubitemid 37410244)
33. Lee HY, Jo SH, Lee C, Baek SH, Bae YS. Differential production of leukotriene B4 or prostaglandin E2 by WKYMVm or serum amyloid A via formyl peptide receptor-like 1. Biochem Pharmacol 2006;72:860-868. (Pubitemid 44301051)
34. Kox WJ, Bone RC, Krausch D, Döcke WD, Kox SN, Wauer H, Egerer K, Querner S, Asadullah K, von Baehr R, et al. Interferon γ-1b in the treatment of compensatory anti-inflammatory response syndrome -a new approach: proof of principle. Arch Intern Med 1997;157:389-393. (Pubitemid 27089964)
35. Doherty GM, Lange JR, Langstein HN, Alexander HR, Buresh CM, Norton JA. Evidence for IFN-γ as a mediator of the lethality of endotoxin and tumor necrosis factor-α. J Immunol 1992;149:1666-1670.
36. Yin K, Gribbin E, Wang H. Interferon-γ inhibition attenuates lethality after cecal ligation and puncture in rats: implication of high mobility group box-1. Shock 2005;24:396-401. (Pubitemid 41416528)
37. Dighe AS, Campbell D, Hsieh CS, Clarke S, Greaves DR, Gordon S, Murphy KM, Schreiber RD. Tissue-specific targeting of cytokine unresponsiveness in transgenic mice. Immunity 1995;3:657-666.